Legochem Biosciences Inc. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, diabetes, fibrosis, obesity, liver diseases and neurological, cardiovascular and renal disorders.
